Close Menu

NEW YORK – AI-driven cancer detection firm Freenome said this week that it has begun a prospective clinical trial to clinically validate the multi-omic and epigenomic test it has developed for blood-based detection of colorectal cancer and pre-cancerous lesions.

The trial, called PREEMPT CRC, will enroll 14,000 asymptomatic, average-risk patients between the ages of 45 and 85 undergoing a screening colonoscopy, and is intended to support a bid for premarket approval by the US Food and Drug Administration.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.